[Impact of preventive administration of antiemetic drugs on risk of acute nausea and vomiting induced by transcatheter arterial chemoembolization in patients with hepatocellular carcinomas - a retrospective study].
This study aimed to evaluate the impact of the preventive administration of antiemetic drugs on the risk of acute nausea and vomiting induced by transcatheter arterial chemoembolization(TACE)in patients with hepatocellular carcinomas(HCCs). From January 2007 to June 2009, a total of 536 patients with HCCs who underwent TACE with a mixture of iodized oil, epirubicin, and porous gelatin particles were included in this retrospective study. Of those patients, 23 out of 357(6.4% ) who had received the 5-HT(3) receptor antagonist before TACE, and 18 out of 179(10.1% )without the medication, experienced vomiting. The multivariate logistic regression model with a predictive success of 92. 4% for vomiting identified significant associations between female gender(odds ratio: 3.73, p<0.001 ), the number of tumors(1.29, p<0.01 ), and administration of pentazocine(11.70, p<0.05)with the risk of vomiting. In contrast, the preventive administration of antiemetic drugs was not included in the model as a significant predictive variable. We therefore conclude from this retrospective study that the 5-HT(3) receptor antagonist did not significantly contribute to preventing the TACE-induced emesis.